These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

6023 related articles for article (PubMed ID: 22460905)

  • 1. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
    Barretina J; Caponigro G; Stransky N; Venkatesan K; Margolin AA; Kim S; Wilson CJ; Lehár J; Kryukov GV; Sonkin D; Reddy A; Liu M; Murray L; Berger MF; Monahan JE; Morais P; Meltzer J; Korejwa A; Jané-Valbuena J; Mapa FA; Thibault J; Bric-Furlong E; Raman P; Shipway A; Engels IH; Cheng J; Yu GK; Yu J; Aspesi P; de Silva M; Jagtap K; Jones MD; Wang L; Hatton C; Palescandolo E; Gupta S; Mahan S; Sougnez C; Onofrio RC; Liefeld T; MacConaill L; Winckler W; Reich M; Li N; Mesirov JP; Gabriel SB; Getz G; Ardlie K; Chan V; Myer VE; Weber BL; Porter J; Warmuth M; Finan P; Harris JL; Meyerson M; Golub TR; Morrissey MP; Sellers WR; Schlegel R; Garraway LA
    Nature; 2012 Mar; 483(7391):603-7. PubMed ID: 22460905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug discovery: Cell lines battle cancer.
    Weinstein JN
    Nature; 2012 Mar; 483(7391):544-5. PubMed ID: 22460893
    [No Abstract]   [Full Text] [Related]  

  • 3. Predicting breast cancer drug response using a multiple-layer cell line drug response network model.
    Huang S; Hu P; Lakowski TM
    BMC Cancer; 2021 May; 21(1):648. PubMed ID: 34059012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-Sensitivity Screening and Genomic Characterization of 45 HPV-Negative Head and Neck Carcinoma Cell Lines for Novel Biomarkers of Drug Efficacy.
    Lepikhova T; Karhemo PR; Louhimo R; Yadav B; Murumägi A; Kulesskiy E; Kivento M; Sihto H; Grénman R; Syrjänen SM; Kallioniemi O; Aittokallio T; Wennerberg K; Joensuu H; Monni O
    Mol Cancer Ther; 2018 Sep; 17(9):2060-2071. PubMed ID: 29970484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Data Mining Approaches for Genomic Biomarker Development: Applications Using Drug Screening Data from the Cancer Genome Project and the Cancer Cell Line Encyclopedia.
    Covell DG
    PLoS One; 2015; 10(7):e0127433. PubMed ID: 26132924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ex vivo modelling of drug efficacy in a rare metastatic urachal carcinoma.
    Mäkelä R; Arjonen A; Härmä V; Rintanen N; Paasonen L; Paprotka T; Rönsch K; Kuopio T; Kononen J; Rantala JK
    BMC Cancer; 2020 Jun; 20(1):590. PubMed ID: 32576176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anticancer drug sensitivity prediction in cell lines from baseline gene expression through recursive feature selection.
    Dong Z; Zhang N; Li C; Wang H; Fang Y; Wang J; Zheng X
    BMC Cancer; 2015 Jun; 15():489. PubMed ID: 26121976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved anticancer drug response prediction in cell lines using matrix factorization with similarity regularization.
    Wang L; Li X; Zhang L; Gao Q
    BMC Cancer; 2017 Aug; 17(1):513. PubMed ID: 28768489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal drug prediction from personal genomics profiles.
    Sheng J; Li F; Wong ST
    IEEE J Biomed Health Inform; 2015 Jul; 19(4):1264-70. PubMed ID: 25781964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy.
    Lee JK; Liu Z; Sa JK; Shin S; Wang J; Bordyuh M; Cho HJ; Elliott O; Chu T; Choi SW; Rosenbloom DIS; Lee IH; Shin YJ; Kang HJ; Kim D; Kim SY; Sim MH; Kim J; Lee T; Seo YJ; Shin H; Lee M; Kim SH; Kwon YJ; Oh JW; Song M; Kim M; Kong DS; Choi JW; Seol HJ; Lee JI; Kim ST; Park JO; Kim KM; Song SY; Lee JW; Kim HC; Lee JE; Choi MG; Seo SW; Shim YM; Zo JI; Jeong BC; Yoon Y; Ryu GH; Kim NKD; Bae JS; Park WY; Lee J; Verhaak RGW; Iavarone A; Lee J; Rabadan R; Nam DH
    Nat Genet; 2018 Oct; 50(10):1399-1411. PubMed ID: 30262818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beyond the limitation of targeted therapy: Improve the application of targeted drugs combining genomic data with machine learning.
    Miao R; Chen HH; Dang Q; Xia LY; Yang ZY; He MF; Hao ZF; Liang Y
    Pharmacol Res; 2020 Sep; 159():104932. PubMed ID: 32473309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison and validation of genomic predictors for anticancer drug sensitivity.
    Papillon-Cavanagh S; De Jay N; Hachem N; Olsen C; Bontempi G; Aerts HJ; Quackenbush J; Haibe-Kains B
    J Am Med Inform Assoc; 2013; 20(4):597-602. PubMed ID: 23355484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenomic agreement between two cancer cell line data sets.
    ;
    Nature; 2015 Dec; 528(7580):84-7. PubMed ID: 26570998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor.
    Guagnano V; Kauffmann A; Wöhrle S; Stamm C; Ito M; Barys L; Pornon A; Yao Y; Li F; Zhang Y; Chen Z; Wilson CJ; Bordas V; Le Douget M; Gaither LA; Borawski J; Monahan JE; Venkatesan K; Brümmendorf T; Thomas DM; Garcia-Echeverria C; Hofmann F; Sellers WR; Graus-Porta D
    Cancer Discov; 2012 Dec; 2(12):1118-33. PubMed ID: 23002168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid identification and validation of novel targeted approaches for Glioblastoma: A combined ex vivo-in vivo pharmaco-omic model.
    Daher A; de Groot J
    Exp Neurol; 2018 Jan; 299(Pt B):281-288. PubMed ID: 28923369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. US cancer institute to overhaul tumour cell lines.
    Ledford H
    Nature; 2016 Feb; 530(7591):391. PubMed ID: 26911756
    [No Abstract]   [Full Text] [Related]  

  • 17. A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors.
    Loboda A; Nebozhyn M; Klinghoffer R; Frazier J; Chastain M; Arthur W; Roberts B; Zhang T; Chenard M; Haines B; Andersen J; Nagashima K; Paweletz C; Lynch B; Feldman I; Dai H; Huang P; Watters J
    BMC Med Genomics; 2010 Jun; 3():26. PubMed ID: 20591134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using drug response data to identify molecular effectors, and molecular "omic" data to identify candidate drugs in cancer.
    Reinhold WC; Varma S; Rajapakse VN; Luna A; Sousa FG; Kohn KW; Pommier YG
    Hum Genet; 2015 Jan; 134(1):3-11. PubMed ID: 25213708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of molecular determinants of tumor sensitivity and resistance to anticancer drugs.
    Quintieri L; Fantin M; Vizler C
    Adv Exp Med Biol; 2007; 593():95-104. PubMed ID: 17265720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A tool for discovering drug sensitivity and gene expression associations in cancer cells.
    Qin Y; Conley AP; Grimm EA; Roszik J
    PLoS One; 2017; 12(4):e0176763. PubMed ID: 28453553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 302.